A Private Guide to Medical Weight Management

Medical weight management should begin with a health assessment and a plan that can be reviewed over time. Nutrition, activity, behavior, medical conditions and medication may all matter. A worthwhile program sets realistic goals without promising that every patient will reach or maintain a particular weight.

Start with eligibility and your health history

Prescription weight-management medicines are intended for specific eligible groups, not everyone who wants to lose a few pounds. For example, current Wegovy labeling includes adults with obesity, or overweight with at least one weight-related condition. The appropriate treatment depends on the exact product, health history and clinical assessment. Wegovy prescribing information.

Bring a medication list and discuss previous weight-management approaches, nutrition, activity, sleep, pregnancy plans and any treatment that was difficult to tolerate. Ask how the program will assess health and function as well as changes on the scale.

Understand what trial results mean

In the STEP 1 trial, adults with overweight or obesity without diabetes received a specified weekly semaglutide regimen or placebo, alongside lifestyle support. The semaglutide group lost more weight on average over 68 weeks. Results from that population and regimen should not be presented as a personal forecast or applied to every formulation. The trial was industry-funded. Read the STEP 1 trial.

A follow-up study found substantial regain after semaglutide and lifestyle intervention stopped. The findings support planning for long-term care rather than treating medication as a short course that guarantees a permanent result. Read the STEP 1 extension.

Safety requires more than supervision alone

Prescribing and follow-up help manage risk but do not make a medicine suitable for everyone. Semaglutide can cause gastrointestinal effects, and its labeling includes serious warnings and contraindications. Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma, MEN2 (an inherited condition that can cause tumors in hormone-producing glands), or a prior serious allergic reaction to semaglutide or its ingredients. Its boxed warning is based on thyroid tumors in rodents; the relevance to humans is unknown. Review current prescribing information.

Discuss serious risks such as pancreatitis, gallbladder problems, dehydration-related kidney injury and severe allergic reactions. Ask which symptoms need urgent assessment or emergency care. Do not change your dose or combine medicines on your own. Follow the product's stop-treatment instructions for warning symptoms and seek prompt medical advice. For weight management, Wegovy labeling advises stopping when pregnancy is recognized and at least two months before a planned pregnancy; coordinate this with your prescriber. Mention other medicines and planned procedures.

Agree on a practical monitoring plan

Before enrolling, ask who prescribes, how often progress is reviewed, what monitoring is appropriate and how dose or treatment decisions are made. Clarify how nutrition and activity support will fit your circumstances, and how the plan will change if the benefit is limited or side effects interfere with daily life.

Request a clear breakdown of visits, medication, testing and other charges. Confirm the exact medicine and source rather than relying on a general ingredient name. This guide does not identify which products are available at the practice.

Plan for maintenance from the beginning

Discuss what happens if treatment must change because of cost, side effects, pregnancy plans or another health issue. Continued follow-up should help you reassess benefits, risks and practical needs. Regain is a reason to revisit the plan, not a moral failure.

Bring the medical weight-management consultation questions to help organize the discussion.

For a personalized discussion in Palm Beach Gardens, contact Luxe Arte Aesthetics. This article provides general education and does not replace an individual medical assessment. Treatment suitability and results vary.

Sources and further reading

• Wegovy prescribing information. Current version accessed November 3, 2026.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183.
• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–1564. doi:10.1111/dom.14725.